Crescent Biopharma
CBIO
69 hedge funds and large institutions have $338M invested in Crescent Biopharma in 2017 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 14 closing their positions.
226% more capital invested
Capital invested by funds: $104M → $338M (+$234M)
186% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 14
60% more funds holding
Funds holding: 43 → 69 (+26)
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
0.16% more ownership
Funds ownership: 0.82% → 0.98% (+0.16%)
70% less call options, than puts
Call options by funds: $337K | Put options by funds: $1.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$13.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.3M |
| 4 |
Millennium Management
New York
|
+$11M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.76M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.56M |
| 3 |
State Street
Boston,
Massachusetts
|
-$927K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$869K |
| 5 |
Renaissance Technologies
New York
|
-$622K |
CBIO Hedge Fund Activity: Q2 2017 in Review
69 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2017, worth a combined $338M — up 226% from $104M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CBIO positions and 14 closed out — a net gain of 26 holders — while 15 added to existing stakes and 10 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $13.2M. The largest seller was Sphera Funds Management, cutting an estimated $3.76M.
- 69 institutional investors held Crescent Biopharma (CBIO) as of Q2 2017, up from 43 in Q1 2017.
- Funds reported $338M of Crescent Biopharma stock for Q2 2017, up 226% quarter-over-quarter.
- 40 funds opened new Crescent Biopharma positions in Q2 2017 and 14 closed out, a net change of +26 holders.
- The largest Crescent Biopharma buyer in Q2 2017 was Jennison Associates, an estimated $13.2M added.
- The largest Crescent Biopharma seller in Q2 2017 was Sphera Funds Management, an estimated $3.76M sold.
Based on aggregated 13F filings for Q2 2017.